Nuo Therapeutics, Inc. (AURX)
USD 1.35
(-1.46%)
USD 1.35
(-1.46%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 3.65 Million USD | 6.95% |
| 2022 | 3.41 Million USD | 3664.89% |
| 2021 | 90.67 Thousand USD | -76.02% |
| 2020 | 378.05 Thousand USD | -62.22% |
| 2019 | 1 Million USD | -63.1% |
| 2018 | 2.71 Million USD | -53.75% |
| 2017 | 5.86 Million USD | -31.71% |
| 2016 | 8.58 Million USD | -51.77% |
| 2015 | 17.8 Million USD | -9.59% |
| 2014 | 19.69 Million USD | -7.14% |
| 2013 | 21.21 Million USD | 8.54% |
| 2012 | 19.54 Million USD | 143.25% |
| 2011 | 8.03 Million USD | 4.33% |
| 2010 | 7.7 Million USD | 52.29% |
| 2009 | 5.05 Million USD | -13.42% |
| 2008 | 5.84 Million USD | -9.39% |
| 2007 | 6.44 Million USD | 26.57% |
| 2006 | 5.09 Million USD | -36.96% |
| 2005 | 8.07 Million USD | -6.3% |
| 2004 | 8.62 Million USD | 93.31% |
| 2003 | 4.46 Million USD | 89.24% |
| 2002 | 2.35 Million USD | -56.87% |
| 2001 | 5.46 Million USD | -83.8% |
| 2000 | 33.72 Million USD | 865.89% |
| 1999 | 3.49 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 893.23 Thousand USD | 10.58% |
| 2024 Q2 | 841.42 Thousand USD | -5.8% |
| 2023 FY | 3.65 Million USD | 6.95% |
| 2023 Q2 | 969.1 Thousand USD | 6.98% |
| 2023 Q1 | 905.87 Thousand USD | -11.58% |
| 2023 Q3 | 967.97 Thousand USD | -0.12% |
| 2023 Q4 | 807.75 Thousand USD | -16.55% |
| 2022 Q1 | 521.81 Thousand USD | 628.27% |
| 2022 FY | 3.41 Million USD | 3664.89% |
| 2022 Q4 | 1.02 Million USD | 8.57% |
| 2022 Q3 | 943.62 Thousand USD | 2.15% |
| 2022 Q2 | 923.72 Thousand USD | 77.02% |
| 2021 Q2 | 6546.00 USD | 14.42% |
| 2021 Q1 | 5721.00 USD | -98.23% |
| 2021 Q4 | 71.65 Thousand USD | 961.35% |
| 2021 Q3 | 6751.00 USD | 3.13% |
| 2021 FY | 90.67 Thousand USD | -76.02% |
| 2020 FY | 378.05 Thousand USD | -62.22% |
| 2020 Q3 | 6254.00 USD | 0.0% |
| 2020 Q4 | 323.63 Thousand USD | 5074.83% |
| 2019 FY | 1 Million USD | -63.1% |
| 2019 Q2 | 402.98 Thousand USD | -35.25% |
| 2019 Q3 | 61.86 Thousand USD | -84.65% |
| 2019 Q4 | -86.44 Thousand USD | -239.73% |
| 2019 Q1 | 622.36 Thousand USD | -0.21% |
| 2018 Q4 | 623.67 Thousand USD | -0.57% |
| 2018 FY | 2.71 Million USD | -53.75% |
| 2018 Q1 | 778.66 Thousand USD | -38.27% |
| 2018 Q3 | 627.21 Thousand USD | -8.13% |
| 2018 Q2 | 682.75 Thousand USD | -12.32% |
| 2017 Q3 | 1.27 Million USD | -66.68% |
| 2017 FY | 5.86 Million USD | -31.71% |
| 2017 Q1 | 1.58 Million USD | -32.97% |
| 2017 Q2 | 3.82 Million USD | 140.75% |
| 2017 Q4 | 1.26 Million USD | -0.95% |
| 2016 Q3 | 1.75 Million USD | -94.45% |
| 2016 Q1 | 2.59 Million USD | -23.48% |
| 2016 Q2 | 31.6 Million USD | 1118.91% |
| 2016 FY | 8.58 Million USD | -51.77% |
| 2016 Q4 | 2.36 Million USD | 34.94% |
| 2015 FY | 17.8 Million USD | -9.59% |
| 2015 Q4 | 3.38 Million USD | -17.09% |
| 2015 Q3 | 4.08 Million USD | -17.44% |
| 2015 Q2 | 4.95 Million USD | -8.03% |
| 2015 Q1 | 5.38 Million USD | 27.16% |
| 2014 Q2 | 5.56 Million USD | 10.4% |
| 2014 Q3 | 4.85 Million USD | -12.79% |
| 2014 Q4 | 4.23 Million USD | -12.81% |
| 2014 FY | 19.69 Million USD | -7.14% |
| 2014 Q1 | 5.04 Million USD | 16.94% |
| 2013 Q2 | 5.72 Million USD | -5.31% |
| 2013 Q4 | 4.31 Million USD | -15.87% |
| 2013 FY | 21.21 Million USD | 8.54% |
| 2013 Q1 | 6.04 Million USD | 30.53% |
| 2013 Q3 | 5.12 Million USD | -10.5% |
| 2012 FY | 19.54 Million USD | 143.25% |
| 2012 Q3 | 4.96 Million USD | -1.67% |
| 2012 Q2 | 5.05 Million USD | 3.4% |
| 2012 Q1 | 4.88 Million USD | 145.52% |
| 2012 Q4 | 4.63 Million USD | -6.77% |
| 2011 FY | 8.03 Million USD | 4.33% |
| 2011 Q2 | 1.99 Million USD | -9.53% |
| 2011 Q3 | 1.84 Million USD | -7.29% |
| 2011 Q4 | 1.99 Million USD | 7.74% |
| 2011 Q1 | 2.2 Million USD | -0.38% |
| 2010 FY | 7.7 Million USD | 52.29% |
| 2010 Q4 | 2.21 Million USD | 7.65% |
| 2010 Q3 | 2.05 Million USD | 1.6% |
| 2010 Q1 | 1.41 Million USD | 0.35% |
| 2010 Q2 | 2.02 Million USD | 42.99% |
| 2009 Q1 | 1.3 Million USD | -16.12% |
| 2009 Q2 | 1.34 Million USD | 2.91% |
| 2009 Q4 | 1.4 Million USD | 40.58% |
| 2009 Q3 | 1 Million USD | -25.31% |
| 2009 FY | 5.05 Million USD | -13.42% |
| 2008 Q3 | 1.29 Million USD | -19.92% |
| 2008 Q2 | 1.61 Million USD | 17.41% |
| 2008 Q1 | 1.37 Million USD | -6.47% |
| 2008 FY | 5.84 Million USD | -9.39% |
| 2008 Q4 | 1.55 Million USD | 20.11% |
| 2007 Q4 | 1.47 Million USD | -49.87% |
| 2007 FY | 6.44 Million USD | 26.57% |
| 2007 Q1 | 1.15 Million USD | 7.28% |
| 2007 Q3 | 2.93 Million USD | 208.27% |
| 2007 Q2 | 952.21 Thousand USD | -17.61% |
| 2006 Q1 | 1.46 Million USD | 26.84% |
| 2006 Q3 | 1.44 Million USD | 31.11% |
| 2006 Q4 | 1.07 Million USD | -25.56% |
| 2006 FY | 5.09 Million USD | -36.96% |
| 2006 Q2 | 1.1 Million USD | -24.64% |
| 2005 FY | 8.07 Million USD | -6.3% |
| 2005 Q1 | 2 Million USD | 1.65% |
| 2005 Q4 | 1.15 Million USD | -56.66% |
| 2005 Q3 | 2.66 Million USD | 18.39% |
| 2005 Q2 | 2.25 Million USD | 11.99% |
| 2004 Q1 | 2.55 Million USD | 73.58% |
| 2004 Q4 | 1.97 Million USD | 1.58% |
| 2004 Q3 | 1.94 Million USD | -9.31% |
| 2004 Q2 | 2.14 Million USD | -15.93% |
| 2004 FY | 8.62 Million USD | 93.31% |
| 2003 Q4 | 1.47 Million USD | 35.36% |
| 2003 FY | 4.46 Million USD | 89.24% |
| 2003 Q3 | 1.08 Million USD | -7.44% |
| 2003 Q2 | 1.17 Million USD | 61.0% |
| 2003 Q1 | 729.12 Thousand USD | -18.02% |
| 2002 FY | 2.35 Million USD | -56.87% |
| 2002 Q3 | 997.66 Thousand USD | 63.09% |
| 2002 Q4 | 889.36 Thousand USD | -10.86% |
| 2002 Q2 | 611.73 Thousand USD | 30.9% |
| 2002 Q1 | 467.31 Thousand USD | 34.4% |
| 2001 Q2 | 2.14 Million USD | -12.04% |
| 2001 Q4 | 347.71 Thousand USD | -63.93% |
| 2001 Q3 | 963.92 Thousand USD | -55.1% |
| 2001 Q1 | 2.44 Million USD | -86.88% |
| 2001 FY | 5.46 Million USD | -83.8% |
| 2000 Q3 | 5.15 Million USD | 49.3% |
| 2000 Q2 | 3.45 Million USD | -47.05% |
| 2000 Q1 | 6.51 Million USD | 0.0% |
| 2000 Q4 | 18.6 Million USD | 261.06% |
| 2000 FY | 33.72 Million USD | 865.89% |
| 1999 FY | 3.49 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 1.33 Million USD | -173.373% |
| Arch Therapeutics, Inc. | 5.04 Million USD | 27.595% |
| Evofem Biosciences, Inc. | 29.55 Million USD | 87.647% |
| Nascent Biotech, Inc. | 2.22 Million USD | -63.718% |
| Rebus Holdings, Inc. | 664 Thousand USD | -449.805% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | 90.201% |
| Qrons Inc. | 643.67 Thousand USD | -467.164% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -837.122% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 93.644% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -778.674% |
| Skye Bioscience, Inc. | 13.54 Million USD | 73.053% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 95.793% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 25.767% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -1294.858% |
| SQZ Biotechnologies Company | 85.61 Million USD | 95.736% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | -25.186% |
| Propanc Biopharma, Inc. | 1.5 Million USD | -143.073% |
| Mesoblast Limited | 5.9 Million USD | 38.145% |
| Marizyme, Inc. | 19.23 Million USD | 81.025% |
| Genus plc | 147.7 Million USD | 97.528% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | 58.417% |
| Pharming Group N.V. | 225.49 Million USD | 98.381% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | -78.196% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -172.127% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | 56.221% |
| ContraFect Corporation | 56.88 Million USD | 93.583% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | 17.193% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | -146.878% |
| IMV Inc. | 37.7 Million USD | 90.319% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | -30.833% |
| MultiCell Technologies, Inc. | 567.42 USD | -643287.085% |
| ONE Bio Corp. | 6.44 Million USD | 43.346% |
| Accustem Sciences Inc. | 3.74 Million USD | 2.555% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 95.752% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 531.96 Thousand USD | -586.272% |
| Q BioMed Inc. | 3.43 Million USD | -6.229% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | 85.229% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | -38.941% |
| Biomind Labs Inc. | 994.18 Thousand USD | -267.207% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 96.325% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | -107.464% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | 45.658% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | -95.815% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 14702.828% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | 77.198% |
| Curative Biotechnology, Inc. | 1.83 Million USD | -98.938% |
| GB Sciences, Inc. | 1.42 Million USD | -157.0% |
| Alpha Cognition Inc. | 9.7 Million USD | 62.386% |
| HST Global, Inc. | 140.9 Thousand USD | -2490.863% |
| CSL Limited | 3.44 Billion USD | 99.894% |
| Wesana Health Holdings Inc. | 1.12 Million USD | -224.533% |
| Halberd Corporation | 74.84 Thousand USD | -4777.885% |
| Enzolytics Inc. | 2.17 Million USD | -67.502% |
| Agentix Corp. | 1.37 Million USD | -166.134% |
| Resverlogix Corp. | 12.71 Million USD | 71.281% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.53 Billion USD | 99.762% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -249.685% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | -51.801% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | -131.152% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | -7.217% |
| AVAX Technologies, Inc. | 7.31 Million USD | 50.061% |
| Zenith Capital Corp. | 8.94 Million USD | 59.178% |
| Genscript Biotech Corporation | 825.34 Million USD | 99.558% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -20855.783% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | -48.686% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -2028.58% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | -90.051% |
| Kadimastem Ltd | 2.41 Million USD | -51.475% |
| Helix BioMedix, Inc. | 1.97 Million USD | -85.124% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 10.86 Million USD | 66.406% |
| BioStem Technologies, Inc. | 22.97 Million USD | 84.11% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -1911.575% |
| LadRx Corporation | 3.81 Million USD | 4.226% |
| Cell Source, Inc. | 4.32 Million USD | 15.597% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -295.308% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -295.308% |
| NovAccess Global Inc. | 2.46 Million USD | -47.996% |
| Affymax, Inc. | 39.38 Million USD | 90.731% |
| Itoco Inc. | 919.14 Thousand USD | -297.186% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | 13.866% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | -226.247% |
| Mobile Lads Corp. | 554.54 Thousand USD | -558.324% |
| CytoDyn Inc. | 18.05 Million USD | 79.783% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -14404.776% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -1558.824% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | -157.13% |
| SYBLEU INC | 160.87 Thousand USD | -2169.268% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | -100.995% |
| International Stem Cell Corporation | 5.27 Million USD | 30.74% |
| Bioxytran, Inc. | 3.82 Million USD | 4.435% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -6834.97% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -17845.765% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | 89.934% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | -125.631% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -396.131% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | -17.348% |
| Neutra Corp. | 243.82 Thousand USD | -1397.29% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | 79.087% |
| PureTech Health plc | 144.59 Million USD | 97.475% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | 82.183% |
| IXICO plc | 4.7 Million USD | 22.441% |
| IntelGenx Technologies Corp. | 8.79 Million USD | 58.501% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 96.9% |
| CSL Limited | 3.89 Billion USD | 99.906% |
| Cellectis S.A. | 97.32 Million USD | 96.249% |